

SGLT2 INHIBITION SPOTLIGHT

Exploring benefits across
diabetes, kidney disease, and
heart failure

BEST PRACTICES FORUM



MONDAY, FEBRUARY 22, 2021



8:00 – 9:30 PM EST

DESCRIPTION:

A case-based discussion on SGLT2 inhibition across the spectrum of diabetes, kidney disease, and heart failure.

FOLLOWING PARTICIPATION IN THIS PROGRAM, PARTICIPANTS WILL BE ABLE TO:

1. To review the protection provided by SGLT2 inhibitors along the clinical spectrum of diabetes and cardio-renal disease.
2. To identify the role of earlier SGLT2 inhibition treatment in the at-risk patient with diabetes.
3. To explore the potential for SGLT2 inhibitors to exert clinical benefits beyond diabetes in the management of heart failure.

AGENDA:

- 8:00 PM** **Opening Comments**
Milan Gupta
- 8:02 PM** **SGLT2 inhibitors across the diabetes and cardio-renal spectrum** - Milan Gupta
- 8:10 PM** **The patient with high-risk diabetes**
Sue Pedersen
- 8:30 PM** **The patient with chronic kidney disease**
Andrew Steele
- 8:50 PM** **The patient with heart failure**
Milan Gupta
- 9:10 PM** **Practical management tips around SGLT2 inhibitor use**
Group discussion - All faculty
- 9:30 PM** **Closing comments**
Milan Gupta

OUR SPEAKERS



Dr. Milan Gupta,
Cardiologist,
Brampton, ON



Dr. Sue Pedersen,
Endocrinologist,
Calgary, AB



Dr. Andrew Steele,
Nephrologist,
Oshawa, ON

Registration: www.ccrnmd.com
For program inquiries, contact info@ccrnmd.com



This program was developed by the Canadian Collaborative Research Network and received an unrestricted educational grant from AstraZeneca.